Clinical Trials

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Urogenital Neoplasms

NCT05413850 2026-05-14

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Phase 1/2 Recruiting

82 enrolled

Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT02496208 2026-05-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

152 enrolled

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT07566156 2026-05-11

EV-309

Phase 3 Recruiting

390 enrolled

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT07572760 2026-05-07

Low to Moderate Load Power Training for Men With Metastatic Prostate Cancer.

Phase NA Recruiting

66 enrolled

Phase 1/2 Active not recruiting

Urogenital Diseases, Genital Diseases, Psychological Well-Being, Genital Neoplasms, Male, Motor Activity, Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms

NCT05067140 2026-05-05

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

152 enrolled

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

NCT04597411 2026-04-30

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

101 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicMyeloidSarcomaThoracic

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT05297734 2026-04-30

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Phase NA Recruiting

2,996 enrolled

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Death, Esophageal Neoplasms, Glioblastoma, Lung Diseases, Lung Neoplasms, Melanoma, Myelodysplastic Syndromes, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Osteosarcoma, Skin Neoplasms, Stomach Neoplasms, Thoracic Neoplasms, Urogenital Neoplasms, Disease Progression, Small Cell Lung Carcinoma

NCT06785636 2026-04-24

P300

Phase 1/2 Recruiting

252 enrolled

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT04461509 2026-03-25

High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy

Phase 2 Completed

62 enrolled 11 charts

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT07103018 2026-03-23

STRIKE-001

Phase 1 Recruiting

144 enrolled

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT07038369 2026-03-17

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

BreastGenitourinaryGynecologic

134 enrolled

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03333616 2026-01-21

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Phase 2 Active not recruiting

100 enrolled

EndocrineGenitourinary

Penile Neoplasms, Urogenital Neoplasms, Adrenocortical Carcinoma, Carcinoma, Small Cell

NCT06680089 2025-12-31

CD70-targeted immunoPET Imaging of Kidney Cancer

Phase 2 Recruiting

300 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms, Urogenital Neoplasms, Urologic Neoplasms

NCT06229366 2025-12-22

ACCEL

142 enrolled

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

NCT06353906 2025-12-08

PRIAM

Phase 2 Recruiting

27 enrolled

Phase NA Active not recruiting

Penile Neoplasms, Urogenital Neoplasms, Urologic Neoplasms, Male Urogenital Diseases

NCT02735252 2025-11-12

PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

156 enrolled

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

NCT05935748 2025-11-12

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Phase 2 Terminated

18 enrolled

Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT03344757 2025-09-11

Health Gatherings - For Your Health After Cancer

Phase NA Completed

188 enrolled 19 charts

Genital Diseases, Male, Genital Neoplasms, Male, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT06237920 2025-09-03

TURANDORELA

Phase 2 Recruiting

90 enrolled

Classical hematologyGenitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Female Urogenital Diseases and Pregnancy Complications, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT05920343 2025-07-10

PREVENT-GU

Phase 2/3 Recruiting

120 enrolled

Urogenital Neoplasms, Urologic Neoplasms, Venous Thromboembolism

NCT05592626 2025-07-09

START-001

Phase 1/2 Recruiting

365 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Abdominal Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Genital Neoplasms, Female, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms, Urogenital Neoplasms, Vulvar Diseases, Vulvar Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Epstein-Barr Virus Infections, Papillomavirus Infections, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03081858 2025-06-27

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

15 enrolled 16 charts

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT05288166 2025-06-27

CYCLONE 3

925 enrolled 12 charts

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

NCT03490838 2025-05-13

PROter

Phase 1 Terminated

27 enrolled

BreastCNSDermatologicGenitourinaryHead & Neck

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT06835426 2025-02-19

High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins

Phase NA Recruiting

150 enrolled

Brain Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, Parathyroid Neoplasms, Prostatic Neoplasms, Skin Neoplasms, Thyroid Neoplasms, Urogenital Neoplasms

NCT04249947 2025-02-17

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Phase 1 Terminated

40 enrolled

GenitourinaryHead & Neck

Carcinoma, Adenoid Cystic, Genital Neoplasms, Male, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Salivary Gland Neoplasms, Urogenital Neoplasms, Carcinoma, Acinar Cell, Carcinoma, Mucoepidermoid, Prostatic Neoplasms, Castration-Resistant

NCT01540994 2025-01-16

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

Phase NA Completed

12 enrolled 7 charts

Phase NA Active not recruiting

Genital Neoplasms, Male, Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms

NCT04811846 2024-12-09

CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood

40 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplastic Cells, Circulating, Neoplasms, Urogenital Neoplasms

NCT06717711 2024-12-05

RCT_LiESWT

Phase 3 Recruiting

158 enrolled

Prostatic Neoplasms, Urogenital Neoplasms

NCT06706921 2024-11-27

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

Phase 4 Recruiting

15 enrolled

Phase EARLY_PHASE1 Completed

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

NCT04067960 2024-08-14

Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer

197 enrolled

CNSGastrointestinalGenitourinaryGynecologic

Brain Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms

NCT02266745 2024-04-05

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

109 enrolled

Genital Neoplasms, Male, Neoplasms by Site, Prostatic Neoplasms, Urogenital Neoplasms

NCT00946881 2024-02-07

Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer

30 enrolled 12 charts

Genital Diseases, Carcinoma, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT05150236 2023-12-15

ANZUP2001

93 enrolled

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT02578797 2023-11-09

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Phase 1 Completed

45 enrolled

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT03636256 2023-08-14

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

36 enrolled 18 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

NCT04880681 2023-05-01

Evaluation of Length and Quality of Prostate Biopsies Taken by a New Biopsy Needle

Phase NA Unknown

60 enrolled

Disease, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT04784507 2022-04-12

En-Bloc Resection of Bladder Tumors

60 enrolled

Urinary Bladder Neoplasms, Urogenital Neoplasms, Urologic Neoplasms

NCT04221828 2022-03-29

Trial of NanoPac Focal Therapy for Prostate Cancer

Phase 2 Terminated

1 enrolled 5 charts

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

NCT04831307 2021-12-03

68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical

Phase NA Unknown

10 enrolled

Neoplasms, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Disease Attributes

NCT05030077 2021-09-01

Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

53 enrolled

Carcinoma, Transitional Cell, Urogenital Neoplasms

NCT04922047 2021-06-11

TACBIN-01

Phase 1/2 Unknown

6 enrolled

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urogenital Neoplasms, Urologic Neoplasms

NCT04644432 2020-11-25

INDIGO

30 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms, Urogenital Neoplasms, Urologic Neoplasms

NCT03490032 2020-11-17

PROfind

30 enrolled 30 charts

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT04225299 2020-11-13

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

Phase 3 Withdrawn